175 related articles for article (PubMed ID: 35641554)
21. Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN).
Nolè F; Minchella I; Colleoni M; Orvieto E; Munzone E; de Braud F; Peruzzotti G; Martinelli G; Zampino MG; Catania C; Pizzamiglio M; Veronesi P; Zurrida S; Galimberti V; Goldhirsch A; Veronesi U
Ann Oncol; 1999 Aug; 10(8):993-6. PubMed ID: 10509165
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer.
Wilke H; Klaassen U; Achterrath W; Losch M; Vanhoefer U; Hayungs J; Harstrick A; Stahl M; Eberhardt W; Becher R; Seeber S
Ann Oncol; 1996 Jan; 7(1):55-8. PubMed ID: 9081392
[TBL] [Abstract][Full Text] [Related]
23. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
24. Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer.
Klaassen U; Harstrick A; Wilke H; Seeber S
Semin Oncol; 1996 Feb; 23(1 Suppl 1):44-7. PubMed ID: 8629037
[TBL] [Abstract][Full Text] [Related]
25. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
26. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer.
Jones SE; Mennel RG; Brooks B; Westrick MA; Allison MA; Paulson RS; Tilmann K; Rea B
J Clin Oncol; 1991 Oct; 9(10):1736-9. PubMed ID: 1919625
[TBL] [Abstract][Full Text] [Related]
28. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Jassem J; Pieńkowski T; Płuzańska A; Jelic S; Gorbunova V; Mrsic-Krmpotic Z; Berzins J; Nagykalnai T; Wigler N; Renard J; Munier S; Weil C;
J Clin Oncol; 2001 Mar; 19(6):1707-15. PubMed ID: 11251000
[TBL] [Abstract][Full Text] [Related]
29. Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Köhne CH; Hiddemann W; Schüller J; Weiss J; Lohrmann HP; Schmitz-Hübner U; Bodenstein H; Schöber C; Wilke H; Grem J
J Clin Oncol; 1995 May; 13(5):1201-8. PubMed ID: 7738622
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Machover D; Goldschmidt E; Chollet P; Metzger G; Zittoun J; Benavides M; Marquet J; Vandenbulcke JM; Misset JL; Schwarzenberg L
NCI Monogr; 1987; (5):193-8. PubMed ID: 3501542
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid.
Mini E; Trave F; Rustum YM; Bertino JR
Pharmacol Ther; 1990; 47(1):1-19. PubMed ID: 2195551
[TBL] [Abstract][Full Text] [Related]
33. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden.
Nolè F; de Braud F; Aapro M; Minchella I; De Pas TM; Zampino MG; Monti S; Andreoni G; Goldhirsch A
Ann Oncol; 1997 Sep; 8(9):865-70. PubMed ID: 9358936
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of paclitaxel and carboplatin versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as a neoadjuvant therapy in patients with inoperable breast cancer.
Akhtar MS; Kousar F; Masood M; Fatimi S; Kokab
J Coll Physicians Surg Pak; 2010 Nov; 20(11):748-52. PubMed ID: 21078249
[TBL] [Abstract][Full Text] [Related]
36. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
[TBL] [Abstract][Full Text] [Related]
37. A pilot study of continuous infusional 5-fluorouracil, doxorubicin and cyclophosphamide in breast cancer.
Mackay HJ; Bissett D; Twelves C; Vasey PA
Clin Oncol (R Coll Radiol); 1999; 11(3):174-8. PubMed ID: 10465471
[TBL] [Abstract][Full Text] [Related]
38. Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study.
Hochster HS; Vogel CL; Burman SL; White R
Oncologist; 2001; 6(3):269-77. PubMed ID: 11423674
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
40. Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Calabresi F; Di Lauro L; Marolla P; Curcio CG; Paoletti G; Calabró A; Giannarelli D; Ballatore P; Foggi CM; Di Palma M
Semin Oncol; 1991 Apr; 18(2 Suppl 4):66-72. PubMed ID: 2031201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
